CELLVIE announces strengthening of leadership team with hiring of CSO & COO.

cellvie, a leader in Therapeutic Mitochondria Transplantation (TMT), is spearheading a ground-breaking treatment modality that harnesses the therapeutic potential of mitochondria, the powerhouses of the cell.

Therapeutic Mitochondria Transplantation, an innovative approach for rescuing and amplifying mitochondria function, was developed by Dr. James McCully at Harvard Medical School. Building upon his pioneering work, cellvie was founded to take TMT from bench to bedside, starting with applications in heart attacks and solid organ transplantation, but expanding the pipeline to include local oligonucleotide delivery.

Dr. Stephen Helliwell joined us as Chief Scientific Officer (CSO), to lead the research team. He is a seasoned expert with nearly 20 years of experience in driving medicinal innovations. With a PhD from the Biozentrum, University of Basel, and a Post-Doc at the Massachusetts Institute of Technology, Stephen's profound understanding of mitochondria biology was honored during his tenure at Novartis, where he initiated and led a mitochondrial dysfunction program, among other research and development activities. In 2020, he joined Rejuveron Life Sciences AG, where he played a pivotal role in building a portfolio of companies focusing on multiple hallmarks of aging.Stephen's invaluable expertise will guide our scientific efforts, optimize our product, and facilitate its readiness for clinical trials.

Also, joining our team is Dr. Martijn Brugman, as Chief Operations Officer, bringing over 20 years of experience in the field of gene therapy, garnered through his work in internationally acclaimed academic institutions and, most recently, at GSK's Cell and Gene Therapy unit. Martijn's extensive background encompasses diverse areas such as small-scale production, cell and molecular biology assay development, and the characterization of cell and gene therapy products. In his role at cellvie, Martijn will lead the evolution of our manufacturing processes, ensuring they meet the stringent regulatory requirements and enabling the reliable large-scale production of our off-the-shelf mitochondria.

As we push the boundaries of Therapeutic Mitochondria Transplantation, we are keen to collaborate with research institutions, healthcare providers, and industry partners who share our vision for pioneering transformative medical breakthroughs.

Join us on our journey to revolutionize medical care and transform lives.

About cellvie AG

Started in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. Schueller, McCully, del Nido and Emani in 2018. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia- reperfusion injury, aging, and beyond since its founding cellvie has successfully expanded its team and operations close to Zurich.

Further information can be found at cellvie.bio.

Back to news